# US 2016/0251348 A1 · PYRIDO[2,3-d]PYRIMIDIN-4-ONE COMPOUNDS AS TANKYRASE INHIBITORS

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0251348 A1
- Document ID: US20160251348A1
- Status: Published application
- Kind: A1
- Application number: 15/027,301
- Filed: 2014-10-29
- Published: 2016-09-01
- Earliest claimed: 2013-11-07
- Assignees: Eli Lilly and Company
- Applicants: Eli Lilly and Company
- Inventors: Marcio CHEDID; Hisham Omer EISSA; Thomas Albert ENGLER; Kelly Wayne FURNESS; Kenneth B. RANK; Timothy Andrew WOODS; Aaron D. WROBLESKI
- Web page: https://patentgrep.com/patent/US20160251348A1

## CPC

- C07D 471/04: Ortho-condensed systems
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 35/04: specific for metastasis
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Pyrido[2,3-d]pyrimidin-4-one compounds, formulations containing those compounds, and their use as tankyrase 1 and 2 inhibitors Formula (I).

## Claims

### Claim 1

A compound having the formula:
wherein:
Y is:
X is —CH2—, —C(CH3)H—, or —C(CH2CH3)H—;
R1 is hydrogen, hydroxy, or halo;
R2 is hydrogen, halo, —CN, —CH3, CF3, or —OCH3;
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

A compound of claim 1 wherein:
Y is:
X is —CH2—, —C(CH3)H—, or —C(CH2CH3)H—;
R1 is hydrogen, hydroxy, or halo;
R2 is hydrogen, halo, —CN, —CH3, CF3, or —OCH3;
or a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 2)

A compound of claim 2 wherein:
Y is
X is —CH2—, —C(CH3)H—, or —C(CH2CH3)H—;
R2 is hydrogen, halo, —CN, —CH3, CF3, or —OCH3;
or a pharmaceutically acceptable salt thereof.

### Claim 4 (depends on 2)

A compound of claim 2 wherein:
Y is:
X is —CH2—, —C(CH3)H—, or —C(CH2CH3)H—;
R1 is hydrogen, hydroxy, or halo;
R2 is hydrogen, halo, —CN, —CH3, CF3, or —OCH3;
or a pharmaceutically acceptable salt thereof.

### Claim 5 (depends on 3)

A compound of claim 3 which is:
8-Methyl-2-[4-(pyrimidin-2-ylmethyl)piperazin-1-yl]-3,5,6,7-tetrahydropyrido[2,3-d]pyrimidin-4-one, or a pharmaceutically acceptable salt thereof;
8-Methyl-2-[4-(1-pyrimidin-2-ylethyl)piperazin-1-yl]-3,5,6,7-tetrahydropyrido[2,3-d]pyrimidin-4-one, or a pharmaceutically acceptable salt thereof;
2-[4-(4-Chloropyrimidin-2-yl)methyl)piperazin-1-yl]-8-methyl-3,5,6,7-tetrahydropyrido[2,3-d]pyrimidin-4-one, or a pharmaceutically acceptable salt thereof; or
2-[4-[(4-methoxypyrimidin-2-yl)methyl]piperazin-1-yl]-8-methyl-3,5,6,7-tetrahydropyrido[2,3-d]pyrimidin-4-one, or a pharmaceutically acceptable salt thereof.

### Claim 6 (depends on 4)

A compound of claim 4 which is:
2-[4-[(3-Bromo-2-pyridyl)methyl]piperazin-1-yl]-8-methyl-3,5,6,7-tetrahydropyrido[2,3-d]pyrimidin-4-one or a pharmaceutically acceptable salt thereof;
2-[4-[(3-Chloro-2-pyridyl)methyl]piperazin-1-yl]-8-methyl-3,5,6,7-tetrahydropyrido[2,3-d]pyrimidin-4-one, or a pharmaceutically acceptable salt thereof;
2-[4-[(3-Fluoro-2-pyridyl)methyl)piperazin-1-yl]-8-methyl-3,5,6,7-tetrahydropyrido [2,3-d]pyrimidin-4-one, or a pharmaceutically acceptable salt thereof; or
2-[[4-(8-Methyl-4-oxo-3,5,6,7-tetrahydropyrido[2,3-d]pyrimidin-2-yl)piperazin-1-yl]methyl]pyridine-3-carbonitrile, or a pharmaceutically acceptable salt thereof.

### Claim 7 (depends on 5)

A compound of claim 5 which is 8-methyl-2-[4-(pyrimidin-2-ylmethyl)piperazin-1-yl]-3,5,6,7-tetrahydropyrido[2,3-d]pyrimidin-4(3H)-one, or a pharmaceutically acceptable salt thereof.

### Claim 8 (depends on 7)

A compound of claim 7 which is 8-Methyl-2-[4-(pyrimidin-2-ylmethyl)piperazin-1-yl]-3,5,6,7-tetrahydropyrido[2,3-d]pyrimidin-4-one 4-methylbenzenesulfonic acid salt.

### Claim 9 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable carrier.

### Claim 10 (depends on 1)

A method of treating a cancer which is colorectal cancer, gastric cancer, liver cancer, breast cancer, triple negative breast cancer, ovarian cancer, medulloblastoma, melanoma, lung cancer, non-small cell lung cancer, pancreatic cancer, prostate cancer, glioblastoma, T-cell lymphoma, T-lymphoblastic lymphoma, T-cell acute lymphocytic leukemia (T-ALL), mantle cell lymphoma, multiple myeloma, chronic myeloid leukemia, or acute myeloid leukemia in a patient comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof.

### Claim at position 11

11-12. (canceled)
